Author Archives: donttradeourlivesaway

Treatment activists at International AIDS Conference, Durban stand in solidarity with breast cancer survivors who need the lifesaving drug ‘trastuzumab’

Roche has a worldwide monopoly on the breast cancer drug ‘trastuzumab’ (marketed under the brand name Herceptin). In South Africa women with HER2 breast cancer can’t afford the drug as it costs ½ a million Rand (approximately USD 34,000 or … Continue reading

Posted in Cancer, Protest&Campaigns, Uncategorized | Leave a comment

Letter from 56 non-profits and experts to Secretary of State John Kerry on pressure on global access to medicines initiatives

To Read: http://keionline.org/sites/default/files/07-20-2016-NGO-Letter-to-State-Dept-re-Colombia-HLP-India.pdf    

Posted in Uncategorized | Leave a comment

AIDS activists demand treatment for all

By Anika Richards, Jamaica Observer| July 18, 2016 DURBAN, South Africa — As the world observed Nelson Mandela International Day, thousands of civil rights activists from South Africa and across the world took to the streets of Durban, South Africa, … Continue reading

Posted in HIV/Aids, Uncategorized | Leave a comment

Six Indian pharma companies get new licences to supply generic drugs

By Shreerupa Mitra-Jha, Firstpost | July 8, 2016 The UN-backed Medicines Patent Pool (MPP) announced on 7 July new generic manufacturing licensing, for antiretrovirals (ARVs) and direct acting anti-viral (DAA) for treating hepatitis C, with seven pharmaceutical companies, six of … Continue reading

Posted in Generics, Hepatitis C, Medicine Patent Pool, Uncategorized | Leave a comment

Mega trade blocs are imperiling India’s role as pharmacy of the world

Secret negotiations are on to bring the stifling provisions of the Trans Pacific Partnership into a proposed regional trade agreement that India is part of. By Latha Jishnu, The Scroll | July 8, 2016 In a kind of pincer movement, … Continue reading

Posted in Generics, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment

The new pharma FDI policy undermines Indian generics, which may make drugs more expensive

By relaxing brownfield pharma FDI norms, the government is making way for multinational corporations to take over ‘Make in India’ generics companies. By Leena Menghaney, The Scroll | June 28, 2016 The Union government’s decision to allow up to 74% … Continue reading

Posted in FDI, Generics, HIV/Aids, Uncategorized | Leave a comment

Making RCEP work

Striking a balance between opening up trade and ‘Make in India’ is essential Source: The Hindu BusinessLine| July 12, 2016 In a major shift of tack, India may reconsider its offer of zero tariffs in its talks with members of … Continue reading

Posted in IPR, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment